Home › Trials › NCT06465186

Treatment of liver disease with efinopegdutide

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Phase 2 Interventional Merck Sharp & Dohme LLC · NCT06465186

This study is testing if efinopegdutide can help people with liver disease caused by fat buildup in the liver feel better by reducing liver fat, inflammation, and scarring.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment80 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorMerck Sharp & Dohme LLC Industry-sponsored
Locations62 sites (Chandler, Arizona and 61 other locations)
Trial IDNCT06465186 on ClinicalTrials.gov

What this trial studies

This clinical study investigates the effectiveness of efinopegdutide in treating compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH). The study aims to determine if the medication can reduce liver fat, inflammation, and fibrosis while also assessing its safety and tolerability among participants. Patients will be randomly assigned to receive either efinopegdutide or a placebo to evaluate the drug's impact on their liver condition.

Who should consider this trial

Good fit: Ideal candidates include individuals with compensated cirrhosis due to MASH, who may also have controlled type 2 diabetes.

Not a fit: Patients with other liver diseases or significant comorbidities may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve liver health and quality of life for patients with MASH.

How similar studies have performed: While there have been studies on similar conditions, the specific approach with efinopegdutide is novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH)
* Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease
* Has history of type 1 diabetes
* Had a bariatric surgical procedure less than 5 years before entry into the study
* History of pancreatitis
* Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke

Where this trial is running

Chandler, Arizona and 61 other locations

+12 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Non-alcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisNAFLDMetabolic Dysfunction-associated Steatotic Liver DiseaseMetabolic Dysfunction-associated Steatohepatitis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.